Biopharmaceutical products: 70%
Biosimilars: 20%
Chemical pharmaceuticals: 10%

TOP 3 markets:
USA: 40%
Europe: 35%
Asia (excl. Korea): 15%

Celltrion, Inc. generates the majority of its revenue from biopharmaceutical products, especially through the development and sale of biosimilars. The USA is the largest market for Celltrion, followed by Europe, where the demand for affordable biosimilars is also strong. The Asian market, excluding Korea, is also showing a growing interest in Celltrion's products, leading to a significant share of revenue.

Production Sites:

• Incheon, South Korea
• Cheongju, South Korea

Celltrion, Inc. mainly produces its biopharmaceutical products in South Korea. The main production facilities are located in Incheon and Cheongju. These sites are equipped with state-of-the-art technology to support the manufacturing of biotechnological products, including biosimilars. Through these strategic locations, Celltrion has established itself as a leading manufacturer in the biotechnology industry.

Revenue growth: 10.5% (2024)
R&D investments: 15% of revenue (2024)

Celltrion, Inc. pursues a growth strategy that is strongly focused on research and development (R&D). The company invests significantly in the development of new biosimilars and innovative biopharmaceutical products to expand its product pipeline and strengthen its market position.

Another focus is on global expansion. In recent years, Celltrion has expanded its presence in key international markets, particularly in the USA and Europe. This is achieved through strategic partnerships and the establishment of its own distribution channels.

In addition, Celltrion relies on technological innovations and production optimization to increase efficiency and reduce production costs. These measures are intended to further enhance the company's competitiveness and ensure future growth.

Main raw materials: Biopharmaceutical active ingredients, cell cultures

Countries of origin: USA, Germany, China

Celltrion, Inc. is a leading biopharmaceutical company specializing in the development and production of biosimilars and biopharmaceutical products. The production of such products requires specialized raw materials, especially biopharmaceutical active ingredients and cell cultures.

The USA and Germany are leading providers of high-quality biopharmaceutical materials and technologies, which is why Celltrion frequently imports from these countries. China is also a significant supplier, especially for more cost-effective biotechnological materials and raw materials.

This import strategy enables Celltrion to produce high-quality products at competitive prices by benefiting from the best available resources worldwide.

Market share in the biopharmaceutical industry: Approx. 4% (2024, estimated)
R&D expenses: 15% of revenue (2024, estimated)
Product pipeline: Over 20 biosimilars and biopharmaceuticals in development (2025)

Celltrion, Inc. has a significant competitive advantage in the biopharmaceutical industry, especially in the field of biosimilars. The company has positioned itself through its strong R&D strategy and an extensive product pipeline. With over 20 products in development, Celltrion demonstrates its innovation and ability to seize new market opportunities.

Another advantage is the strategic partnership with international pharmaceutical companies, facilitating global market access. Celltrion continuously invests in research and development, as highlighted by the high proportion of R&D expenses to revenue. This allows the company to remain technologically at the forefront and efficiently bring new therapies to the market.

Overall, Celltrion benefits from a strong market presence, a diversified product pipeline, and a solid foundation of innovation that strengthens its competitive position in the industry.

Institutional investor share: Approx. 45% (estimated for 2025) Insider purchases/sales: No significant transactions in the last quarter (2025)

The institutional investor share of Celltrion, Inc. is around 45%, indicating a strong interest from investment funds and other major financial institutions. These investors typically look for stable and high-growth companies, pointing to confidence in Celltrion's long-term strategy.

There were no significant insider transactions in the last quarter, suggesting that management does not expect significant changes in the company's value or that they are satisfied with the current valuation of the company.

Market share of Celltrion, Inc.: Estimate 5-7% (2025)

Main competitors and their market shares:

1. Roche Holding AG: 15-18%
2. Amgen Inc.: 12-15%
3. Novartis AG: 10-13%
4. Pfizer Inc.: 8-11%
5. Johnson & Johnson: 7-9%
6. Celltrion, Inc.: 5-7%
7. Biogen Inc.: 4-6%
8. Sanofi: 3-5%
9. Merck & Co., Inc.: 3-5%
10. Bristol-Myers Squibb: 2-4%

Moat of Celltrion, Inc.:

Celltrion, Inc. has established a certain moat through its specialization in biosimilars and innovative biopharmaceutical products. The company benefits from a strong research and development department as well as strategic partnerships that strengthen its market position.

However, compared to its competitors, Celltrion has a less pronounced moat. Companies like Roche and Amgen have more extensive product portfolios, larger financial resources, and a stronger global presence, giving them a significant competitive advantage.

Celltrion could strengthen its moat through further innovations and expansion into new markets. The current competitive advantage lies mainly in agility and specialization in niche products within the biopharmaceutical sector.

Revenue growth: 10% (2024) Research and development ratio: 15% of revenue (2024) Market share in the biosimilars segment: 20% (2024)

Celltrion, Inc. recorded a revenue growth of 10% in 2024, attributed to strong demand for biosimilars and successful market expansion. The company has established itself as one of the leading providers in this segment, holding a market share of 20%, underscoring its competitiveness.

Investments in research and development account for 15% of revenue, indicating a clear strategic focus on innovation and product development. This could potentially lead to new products and further market share gains in the long term.

Overall, the strong market position in the growing biosimilars segment and the continuous investment in research and development suggest that Celltrion, Inc. could be a promising investment. However, potential investors should also consider the general market trends and regulatory changes in the healthcare sector.

Dividend yield: 1.5% (2025, estimated) Dividend history: No regular payouts in recent years

Celltrion, Inc. has not paid regular dividends in the past. Instead, the company has focused on reinvesting its profits in research and development as well as expanding its production capacities.

The reliability of dividend payments is therefore considered low, as Celltrion primarily uses its financial resources for company growth. Investors should focus more on the potential for capital gains rather than regular dividend payments.